Iovance Biotherapeutics (IOVA) Equity Average (2016 - 2025)
Historic Equity Average for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to $700.4 million.
- Iovance Biotherapeutics' Equity Average fell 915.83% to $700.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $700.4 million, marking a year-over-year decrease of 915.83%. This contributed to the annual value of $647.5 million for FY2024, which is N/A changed from last year.
- Per Iovance Biotherapeutics' latest filing, its Equity Average stood at $700.4 million for Q3 2025, which was down 915.83% from $733.2 million recorded in Q2 2025.
- Over the past 5 years, Iovance Biotherapeutics' Equity Average peaked at $771.0 million during Q3 2024, and registered a low of $511.0 million during Q1 2023.
- Over the past 3 years, Iovance Biotherapeutics' median Equity Average value was $700.4 million (recorded in 2025), while the average stood at $675.6 million.
- Per our database at Business Quant, Iovance Biotherapeutics' Equity Average soared by 2374.82% in 2024 and then plummeted by 915.83% in 2025.
- Iovance Biotherapeutics' Equity Average (Quarter) stood at $629.3 million in 2023, then rose by 17.9% to $741.9 million in 2024, then decreased by 5.6% to $700.4 million in 2025.
- Its Equity Average stands at $700.4 million for Q3 2025, versus $733.2 million for Q2 2025 and $739.1 million for Q1 2025.